Lung Disease Clinical Trials
A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 42 clinical trials
Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
Surgery is the best treatment for patients with Stage I or II lung cancer; however, nearly 60% of patients have recurrence. Additional immunotherapeutic agents given before surgery may be greatly reduce recurrence.
- 0 views
- 19 Feb, 2024
- 1 location
Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
Normal 0 false false false EN-US X-NONE X-NONE You are being invited to participate in a research study because you have Bronchiolitis Obliterans Syndrome. Bronchiolitis Obliterans Syndrome (BOS) is a long term (chronic) rejection process that can occur in the transplanted lungs. Itacitinib works by blocking your body from producing …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 09517: Phase II study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 06518: A Phase 2 Precision Oncology Study of Biomarker-Directed Pembrolizumab-Based Combination Therapy for Advanced Non-Small Cell Lung Cancer
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation).
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer
The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer that has a mutation in a key cancer gene called KRAS, and the cancer has spread to other parts of their body.
- 0 views
- 19 Feb, 2024
- 1 location
Pulmonary Vascular Complications of Liver Disease 3
The main purpose of this study is to determine if certain genes, hormones, or other factors predict the risk of developing lung vessel disease in patients with liver disease and whether they determine outcome. Patients in need of a liver transplant evaluation or have portopulmonary hypertension or are suspected of …
- 0 views
- 19 Feb, 2024
- 1 location
Substudy: Understanding COVID-19 vaccine responses in the setting of immunotherapy
Anti-PD-1 antibody infusion is now increasingly being tested for other cancers as well, with relatively recent FDA-approval for use in metastatic non-small cell lung cancer, renal cell carcinoma, and metastatic or recurrent head and neck squamous cell carcinoma. This study is designed to better understand antibody responses in the setting …
- 0 views
- 19 Feb, 2024
- 1 location
Intraoperative molecular imaging of pulmonary nodules by BY SGM-101
Normal 0 false false false EN-US X-NONE X-NONE The research study is being conducted to determine if a new type of contrast agent can detect your cancer cells and to determine if the cancer has spread. The dye is unique for the following reasons: · It is not radioactive · …
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 1/2 Randomized Double-Blind Placebo-Controlled Combined Single and Multiple Ascending Dose Study Evaluating the Safety Tolerability and Biological Activity of MRT5005 (COhCFTR mRNA/ICE LNP) Administered by Nebulization to Adult Subjects with Cystic Fibrosis
This research study is being done to study a new way to possibly treat cystic fibrosis lung disease. The investigational drug to be tested in the present study is known by its code name MRT5005. MRT5005 consists of very small particles containing messenger ribonucleic acid (mRNA), which has the genetic …
- 0 views
- 19 Feb, 2024
- 1 location